1. Introduction {#sec1}
===============

Tuberculosis (TB) remains an important problem for the public health worldwide, especially in developing countries. Of the five countries with the largest number of incident cases in 2012, China (0.9 million--1.1 million) ranked the second just next to India, which accounted for 12% of the global cases alone \[[@B1]\]. Recently the emerging of drug-resistant TB (DR-TB) is becoming an important threat to TB control and public health worldwide \[[@B2], [@B3]\], and according to the National Survey of Drug-Resistant Tuberculosis in China, 5.7% of new TB patients and 25.6% of the previously treated cases were multi-drug-resistant TB (MDR-TB) \[[@B4]\]. In the last decade, genotyping of*Mycobacterium tuberculosis* (*M. tuberculosis*) has significantly enhanced our understanding of TB epidemiology by detecting suspected outbreaks and by tracing the infection routine. Such molecular methods like spacer oligonucleotide typing (Spoligotyping) and mycobacterial interspersed repetitive unit- (MIRU-) variable number tandem repeats (VNTR) typing have been used to characterize clinical*M. tuberculosis* isolates in China \[[@B5]--[@B7]\]. Obtaining the characteristic of*M. tuberculosis* isolates circulating in an area is helpful for understanding and controlling the spread of TB infection.

Although molecular epidemiology study of TB has been taken out in some area in China \[[@B8]--[@B10]\], few efforts have been made for the collection of DNA fingerprinting data based on the mutation profiles of isolates from the western region of China such as Sichuan province. Sichuan is a province that is located in southwestern China, with a population of approximately 87 million inhabitants. Sichuan contained the second-largest number of TB cases among Chinese provinces, where the prevalence of both TB and drug-resistant TB was much higher than the average level in China \[[@B11]\]. The total cases of TB in Sichuan province are estimated to be about 272,000 in 2006 and the new cases found in 2006 were more than 70,000 \[[@B12]\]. So the genetic and drug-resistant characteristics analysis of clinical*M. tuberculosis* isolates from this area may give us some benefits on TB control in China.

The aim of this study was to identify and genetically characterize the*M. tuberculosis* isolates circulating in Zigong, southern Sichuan, and to explore the distribution of drug resistance profiles across the major Spoligotyping-defined*M. tuberculosis* genotypes.

2. Material and Methods {#sec2}
=======================

2.1. Bacterial Strains and DNA Samples {#sec2.1}
--------------------------------------

A total of 265 clinical*M. tuberculosis* isolates were collected from Zigong, Sichuan, in 2010. Chromosomal DNA was extracted from fresh bacteria cultures on the Lowenstein-Jensen (L-J) medium. A loopful of mycobacterial colonies were suspended in 400 *μ*L TE buffer (pH 8.0) and then boiled for 10 min. The suspension was centrifuged at 12,000 rpm for 10 min, and the supernatant was served as PCR template and stored at −20°C.

2.2. Spoligotyping {#sec2.2}
------------------

Spoligotyping was performed as described previously by Kamerbeek et al. \[[@B13]\]. The results were entered into Excel spreadsheets in a binary format and compared with SITVITWEB database \[[@B14]\], which is a publicly available international multimarker database for studying*Mycobacterium*.

2.3. MIRU-VNTR Typing {#sec2.3}
---------------------

VNTR analysis was performed by the amplification of 24 genomic loci, the scheme of which has been described by Supply et al. \[[@B15]\]. Each VNTR locus was amplified individually in 20 *μ*L reaction mixture containing 1x PCR GC Buffer I (Takara Bio Inc.), 5 pmol of each primer set, 200 *μ*M of each dNTP, 0.5 U of DNA Taq Polymerase (Takara Bio Inc.), and 1.5 ng of DNA template. An initial denaturation step of 5 min at 95°C was followed by 35 cycles at 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min, with a final extension at 72°C for 10 min. The PCR products were analyzed by electrophoresis on 2% agarose gel using 100 bp DNA ladder as size markers. The H37Rv strain was included as a positive control for each amplification reaction and run as an additional control for accuracy, and then the copy number of each locus was calculated by using the Image Lab software (Bio-Rad).

2.4. Drug Susceptibility Testing {#sec2.4}
--------------------------------

Drug susceptibility testing of those 265 strains to the four first-line drugs (rifampicin \[RFP\], isoniazid \[INH\], streptomycin \[SM\], and ethambutol \[EMB\]) and four second-line drugs (amikacin \[AMK\], kanamycin \[KA\], ofloxacin \[OFLX\], and capreomycin \[CPM\]) was performed by using proportion method recommended by WHO \[[@B16]\]. Multi-drug-resistant TB (MDR-TB) is the isolate that was resistant to at least the two first-line anti-TB drugs, RFP and INH, based on the WHO definition \[[@B17]\].

2.5. Computer Analysis {#sec2.5}
----------------------

The Spoligotyping and MIRU-VNTR typing results of all the*M. tuberculosis* clinical isolates were analyzed by the BioNumerics program (Windows 7, version 5.10; Applied Maths, Kortrijk, Belgium). Clusters were defined as groups that the*M. tuberculosis* isolates have identical Spoligotyping or MIRU-VNTR patterns. The dendrograms based on the Spoligotyping and 24 VNTR loci data were conducted using UPGMA protocol. The Hunter-Gaston discrimination index (HGDI) for the 24 VNTR loci was calculated using the previously reported formula \[[@B18]\]. The HGDI of each VNTR locus was calculated by using the web based VNTR Diversity and Confidence Extractor (V-DICE <http://www.hpa-bioinformatics.org.uk/cgi-bin/DICI/DICI.pl>).

2.6. Statistical Analysis {#sec2.6}
-------------------------

Chi-squared tests were used to compare the proportions of DR-TB and the distribution of genotypes in different groups. All tests of significance were two-sided and the significant threshold was set at 0.05.

3. Results {#sec3}
==========

3.1. Demographic Characters {#sec3.1}
---------------------------

All of the 265 clinical isolates were cultured from sputum samples of different TB patients in Zigong CDC, Sichuan province, in 2010. And for the 265 TB patients, 44 (16.60%) were previously treated, 139 (52.45%) were in the 30- and 60-year-old age group, 39 (14.72%) female and 209 (78.87%) male patients with other 17 (6.41%) gender uncertain patients, and no difference about these factors between Beijing and non-Beijing family strains was found at *p* \< 0.05 level ([Table 1](#tab1){ref-type="table"}).

3.2. Spoligotyping {#sec3.2}
------------------

Based on the Spoligotyping results, all of the 265 isolates were subdivided into 64 Spoligotypes, among which 49 patterns were unique whereas other 216 isolates were grouped into 15 clusters containing 2 to 128 isolates. Following comparison with the SITVITWEB database, 239 isolates were clustered into 40 shared international types (SITs), whereas the other 26 isolates that had not been described in the database were referred to as "Orphan." Family assignment revealed that 143 strains had the classical Beijing family-specific or Beijing family-like Spoligotyping pattern. We treated all these 143 isolates as Beijing family strains ([Figure 1](#fig1){ref-type="fig"}). In total, the Beijing family is clearly the most prevalent genetic family in our research setting (143/265, 53.96%), followed by T family (80/265, 30.19%) and H family (9/265, 3.40%).

3.3. MIRU-VNTR Typing {#sec3.3}
---------------------

Exploitable VNTR results (defined as less than 4 missing values) were obtained for 262 isolates out of 265 isolates. Using the 24 polymorphic loci, all of the 262*M. tuberculosis* isolates were identified to 257 different VNTR types and 3 main clusters. A total of 253 isolates had unique profiles. The remaining 9 isolates formed 4 clusters (2 to 3 isolates) ([Figure 2](#fig2){ref-type="fig"}). The total Hunter-Gaston discrimination index (HGDI) for all of the 263 isolates was 0.9995, and that of Beijing and non-Beijing family isolates was 0.9987 and 0.9992, respectively; the HGDI of each of the 24 VNTR loci were shown in [Table 2](#tab2){ref-type="table"}.

3.4. Drug-Resistant Phenotypic Profiles {#sec3.4}
---------------------------------------

Among all the 265 isolates, 72 (27.17%) were resistant to at least one of the eight tested anti-TB drugs, and other 193 (72.83%) were sensitive. Of the 72 drug-resistant isolates, 48 (18.11%) were INH-resistant, 40 (15.09%) were RIF-resistant, 32 (12.08%) were SM-resistant, 17 (6.42%) were EMB-resistant, 32 (12.08%) were OFLX-resistant, and 36 (13.58%) of those drug-resistant strains were MDR-TB; no XDR-TB was found in this study ([Table 3](#tab3){ref-type="table"}). When grouped by gender or age group like previous report \[[@B8]\], no relationship was found with the isolate\'s character of drug resistance. But having been treated before may play an important role with the drug resistance, not only for the drug-resistant TB (*χ* ^2^ = 11.2680, *p* \< 0.05) but also for the MDR-TB (*χ* ^2^ = 18.8983, *p* \< 0.05) ([Table 4](#tab4){ref-type="table"}).

3.5. Relationship between Beijing Family and Drug Resistance {#sec3.5}
------------------------------------------------------------

According to the demographic data, no matter whether they are grouped by gender, age groups, or even treatment history, there was no difference of the infection rate between Beijing and non-Beijing family isolates observed ([Table 1](#tab1){ref-type="table"}). And for the Spoligotyping patterns and DST results, of the 143 Beijing family isolates, 41 (28.67%) were drug-resistant to at least one of the eight anti-TB drugs of which 23 (16.08%) were MDR-TB. While, in the 122 non-Beijing isolates, 31 (25.41%) were drug-resistant and 13 (10.66%) were MDR-TB, no difference of the drug resistance proportion was found between Beijing and non-Beijing family isolates ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

Previous research report has reviewed that Beijing family is prevalent (57.89%) in Sichuan province \[[@B6]\], and according to the Spoligotyping results in this study, the proportion of Beijing family is about 54.34% in southern Sichuan, a little lower than that of the previous report. This may be because our study was just focused on the prevalence isolates in Zigong, and more isolates were included in this study which could afford much more representativeness. But this still conforms to the former reports that the most prevalent isolate here was Beijing family strains and the highest prevalence of Beijing family was found in northern China, followed by central and southern China \[[@B6], [@B7]\]. Besides, T genotype was the second major epidemic genotype circulating in this area and was also consistent with the previous study \[[@B19]\]. This may indicate that non-Beijing family strains also played an important role in the high tuberculosis burden in Sichuan and some other provinces that are located in southern China \[[@B6], [@B7]\].

Spoligotyping has been considered as the gold standard for Beijing family identification, as it is simple and efficient. But the discrimination of Spoligotypes for Beijing family is very low and it cannot further differentiate Beijing family strains, as Beijing family strains always show characteristic homological Spoligotyping pattern \[[@B20]\]. For the 24 loci MIRU-VNTR typing method, even the discrimination of each locus is different, but when we combined them together a high resolution was acquired ([Table 2](#tab2){ref-type="table"}). As the MIRU-VNTR genotyping is considered to be faster and easier to perform, the results are in digital format which can be easily compared between laboratories. Thus, if conditions allow, we suggest Spoligotyping and MIRU-VNTR genotyping should be taken out at the same time, to investigate in more detail characters of the selected isolates. But for some loci the HGDI were so low; different countries could select specific loci for genotyping. And for the three main clusters of the UPGMA dendrogram in [Figure 2](#fig2){ref-type="fig"}, one formed by Beijing family isolates and other two within non-Beijing family isolates, but no difference was found between them for difference factors, like drug resistance and patient age group.

In our study, 27.17% (*n* = 72) of the isolates were resistant to at least one of the eight anti-TB drugs, and 13.58% (*n* = 36) were MDR-TB; no XDR-TB was found in this study. These have some difference with the whole nation\'s status \[[@B4]\]. Firstly, we focused on the target area here in Sichuan province; the demographic and*M. tuberculosis* infectious status in this area may have some differences with those of the whole nation. Secondly, the isolates selected into our study may also have some differences with that of the previously report. Also in our study we found that the treatment history may play an important role with the drug resistance, not only for drug-resistant TB but also for MDR-TB ([Table 4](#tab4){ref-type="table"}); thus the management of TB patients should be strengthened. And as the drug-resistant TB may be the most important challenge to achieve the goals of stopping TB, much more attention should be paid to it.

As Beijing family strains were prevalent in this area (143/265, 53.96%) and in some reports, Beijing family has been considered to be related to TB outbreak and drug resistance \[[@B21]--[@B24]\], while some are not \[[@B25]--[@B27]\]. Referring to our study, the chi-square analysis showed that there was no significant difference between the Beijing and non-Beijing family strains in terms of their drug resistance proportion and patient age group. This may be because Beijing family is the genetic aspect but the drug resistance is a biological aspect of one*M. tuberculosis* isolate, and there is no constant relationship between them.
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###### 

Demographic data of the 265 isolates in Zigong, China.

  ----------------------------------------------------------------------------------------
  Factors           Whole\        Beijing\      Non-Beijing\   *χ* ^2^ ^*∗*^ (*p* value)
                    (*n* = 265)   (*n* = 143)   (*n* = 122)    
  ----------------- ------------- ------------- -------------- ---------------------------
  Sex                                                           

   Female           39            25            14             1.6036 (0.2054)

   Male             209           111           98             

   Unknown          17            7             10              

  Age                                                           

   \<30             27            19            8              6.9592 (0.0732)

    *⩾*30           139           79            60             

    *⩾*60           69            30            39             

    *⩾*75           9             6             3              

   Unknown          21            9             12              

  Treated before?                                               

   Yes              44            25            19             0.1732 (0.6773)

   No               221           118           103            
  ----------------------------------------------------------------------------------------

*∗*: evaluated the difference between Beijing and non-Beijing family strains.

###### 

HGDI of the 24 MIRU-VNTR loci for the whole sample, Beijing and non-Beijing family isolates.

  ----------------------------------------------------
  Locus     Whole\        Beijing\      Non-Beijing\
            (*n* = 265)   (*n* = 143)   (*n* = 122)
  --------- ------------- ------------- --------------
  ETRA      0.594         0.262         0.606

  ETRB      0.374         0.068         0.504

  ETRC      0.110         0.069         0.159

  ETRD      0.303         0.028         0.540

  ETRE      0.592         0.245         0.202

  MIRU02    0.030         0.000         0.065

  MIRU10    0.576         0.263         0.242

  MIRU16    0.283         0.181         0.392

  MIRU20    0.246         0.240         0.254

  MIRU23    0.124         0.108         0.143

  MIRU24    0.015         0.014         0.017

  MIRU26    0.739         0.570         0.598

  MIRU27    0.328         0.028         0.523

  MIRU39    0.521         0.082         0.097

  MIRU40    0.551         0.485         0.619

  Mtub04    0.620         0.363         0.622

  Mtub21    0.806         0.710         0.571

  Mtub29    0.096         0.069         0.127

  Mtub30    0.496         0.119         0.182

  Mtub34    0.095         0.042         0.157

  Mtub39    0.511         0.267         0.647

  QUB11b    0.854         0.745         0.796

  QUB26     0.723         0.571         0.821

  QUB4156   0.052         0.081         0.017
  ----------------------------------------------------

###### 

Prevalence of anti-TB drug resistance among 265 isolates in Sichuan province^*∗*^.

  -------------------------------------------------------------------------------------------------------------------
  Anti-TB drugs                    Whole\              Beijing\            Non-Beijing\         *χ* ^2^ (*p* value)
                                   (*n* = 265)         (*n* = 143)         (*n* = 122)          
  -------------------------------- ------------------- ------------------- -------------------- ---------------------
  Isoniazid                        18.11% (*n* = 48)   19.44% (*n* = 28)   16.53% (*n* = 20)    0.45 (0.5019)

  Rifampicin                       15.09% (*n* = 40)   18.75% (*n* = 27)   10.74% (*n* = 13)    3.48 (0.0623)

  Streptomycin                     12.08% (*n* = 32)   13.89% (*n* = 20)   9.92% (*n* = 12)     1.07 (0.3014)

  Ethambutol                       6.42% (*n* = 17)    7.64% (*n* = 11)    4.96% (*n* = 6)      0.84 (0.3583)

  Ofloxacin                        12.08% (*n* = 32)   9.03% (*n* = 13)    15.70% (*n* = 19)    2.61 (0.1065)

  Resistant to any anti-TB drugs   27.17% (*n* = 72)   28.47% (*n* = 41)   25.62 % (*n* = 31)   0.35 (0.5519)

  MDR-TB                           13.58% (*n* = 36)   15.97% (*n* = 23)   10.74% (*n* = 13)    1.65 (0.1986)
  -------------------------------------------------------------------------------------------------------------------

*∗*: all 265 isolates were sensitive to other three kinds of anti-TB drugs, and Pearson *χ* ^2^ and *p* value were evaluated between the Beijing and non-Beijing family strains.

###### 

Prevalence of anti-TB drug resistance among 265 isolates by factors.

  Factors    Sensitive TB (*n* = 193)   Any drug resistance TB (*n* = 72)   *χ* ^2^ (*p* value)    Non-MDR-TB (*n* = 229)   MDR-TB (*n* = 36)   *χ* ^2^ (*p* value)
  ---------- -------------------------- ----------------------------------- ---------------------- ------------------------ ------------------- ----------------------
  Sex                                                                                                                                            
   Female    29                         10                                  0.1097 (0.7405)        34                       5                   0.0095 (0.9225)
   Male      150                        59                                  181                    28                                           
   Unknown   14                         3                                                          14                       3                    
  Age                                                                                                                                            
   \<30      22                         5                                   4.1444^*∗*^ (0.2402)   23                       4                   4.8455^*∗*^ (0.1579)
    *⩾*30    93                         46                                  115                    24                                           
    *⩾*60    52                         17                                  64                     5                                            
    *⩾*75    8                          1                                   9                      0                                            
   Unknown   18                         3                                                          18                       3                    
  Treated?                                                                                                                                       
   Yes       23                         21                                  11.2680 (0.0008)       29                       15                  18.8983 (0.0000)
   No        170                        51                                  200                    21                                           

*∗*: evaluated by the Fisher\'s exact test.
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